ImmunityBio (IBRX) stated its Phase 2 QUILT-2.005 trial for Anktiva plus BCG remains on track for final analysis and a regulatory filing in 2026. An independent committee confirmed sufficient statistical power with half the participants enrolled. IBRX stock fell 2% pre-market after a 9% gain in the previous session.